The present invention provides a pharmaceutical combination comprising (a) a B-Raf inhibitor which is Compound A or a pharmaceutically acceptable salt thereof, (b) an EGFR inhibitor, wherein the EGFR inhibitor is cetuximab or erlotinib and, optionally, (c) a PI3K-α inhibitor, wherein the PI3K-α inhibitor is Compound B or a pharmaceutically acceptable salt thereof, wherein the combination is adapted for simultaneous, separate or sequential administration. The present invention also provides the uses of such combination in the treatment of proliferative diseases and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
